MDGL SEC Filing News — Madrigal Pharmaceuticals, Inc.

Latest SEC filings for Madrigal Pharmaceuticals, Inc. (MDGL) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-28.

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Sector: Healthcare Industry: Biotechnology Market Cap: $10.3B
20
Total Filings
0
Bullish Classifications
5
Bearish Classifications
11
Insider Transactions
3
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for MDGL currently lean bearish. Of the 20 filing records displayed, 5 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
MDGL Filing Activity Snapshot 2026-06-01 — 2026-09-28
Insider Transactions (Form 4)
0 buys vs 4 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$25.83M
PAUL FRIEDMAN · 2026-09-28
50,000 shares · Form 144
Form 144 Notices
5
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 11 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 11 filings in this group are Form 4s for Madrigal Pharmaceuticals, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 11 insider filings shown, the breakdown is 7 compensation award and 4 open-market sale. 4 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×7
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×4
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Form 4 Open-market sale Insider Selling 2026-09-11

MDGL insider Sibold William John (Director, President and CEO) sold 11,583 shares (~$6.24M)

Sibold William John, listed as Director, President and CEO at MADRIGAL PHARMACEUTICALS, INC., reported an open-market sale of 11,583 MDGL shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 131 $527.88 $69.2K
S Open-market sale 347 $529.27 $183.7K
S Open-market sale 522 $530.23 $276.8K
S Open-market sale 368 $531.99 $195.8K
S Open-market sale 512 $533.09 $272.9K
S Open-market sale 396 $534.20 $211.5K
S Open-market sale 644 $535.27 $344.7K
S Open-market sale 1,040 $536.11 $557.6K
S Open-market sale 640 $537.17 $343.8K
S Open-market sale 520 $538.30 $279.9K
S Open-market sale 215 $539.03 $115.9K
S Open-market sale 505 $540.19 $272.8K
S Open-market sale 362 $541.65 $196.1K
S Open-market sale 160 $542.55 $86.8K
S Open-market sale 60 $533.09 $32.0K
S Open-market sale 106 $534.06 $56.6K
S Open-market sale 218 $535.94 $116.8K
S Open-market sale 160 $537.62 $86.0K
S Open-market sale 687 $540.59 $371.4K
S Open-market sale 368 $541.64 $199.3K
S Open-market sale 1,202 $542.60 $652.2K
S Open-market sale 1,539 $544.02 $837.3K
S Open-market sale 761 $544.83 $414.6K
S Open-market sale 120 $546.38 $65.6K
Filing: Form 4 (Insider Transaction) Insider: Sibold William John (Director, President and CEO) Shares: 11,583 Est. Value: $6.24M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-20

MDGL insider Kelley Shannon T (General Counsel) sold 664 shares (~$341.9K)

Kelley Shannon T, listed as General Counsel at MADRIGAL PHARMACEUTICALS, INC., reported an open-market sale of 664 MDGL shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 664 $514.97 $341.9K
Filing: Form 4 (Insider Transaction) Insider: Kelley Shannon T (General Counsel) Shares: 664 Est. Value: $341.9K
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-08-18

MDGL insider Form 4 filed for equity award, exercise, or tax withholding

REED JOHN C (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 647 — —
A Compensation award derivative · Stock Option (Right to Buy) 1,078 — —
Filing: Form 4 (Insider Transaction) Insider: REED JOHN C (Director) Shares: 647
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-20

MDGL insider Sibold William John (Director, President and CEO) sold 2,500 shares (~$1.37M)

Sibold William John, listed as Director, President and CEO at MADRIGAL PHARMACEUTICALS, INC., reported an open-market sale of 2,500 MDGL shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 50,000 — —
S Open-market sale 140 $542.75 $76.0K
S Open-market sale 110 $543.79 $59.8K
S Open-market sale 545 $544.71 $296.9K
S Open-market sale 275 $545.71 $150.1K
S Open-market sale 269 $547.08 $147.2K
S Open-market sale 680 $547.70 $372.4K
S Open-market sale 47 $548.87 $25.8K
S Open-market sale 153 $550.01 $84.2K
S Open-market sale 1 $550.72 $550.72
S Open-market sale 280 $555.05 $155.4K
M Option exercise derivative · Performance Restricted Stock Units 50,000 — —
Filing: Form 4 (Insider Transaction) Insider: Sibold William John (Director, President and CEO) Shares: 2,500 Est. Value: $1.37M
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-18

MDGL insider Form 4 filed for equity award, exercise, or tax withholding

Taub Rebecca (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 454 — —
A Compensation award derivative · Stock Option (Right to Buy) 766 — —
Filing: Form 4 (Insider Transaction) Insider: Taub Rebecca (Director) Shares: 454
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-18

MDGL insider Form 4 filed for equity award, exercise, or tax withholding

Levy Richard S (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 454 — —
A Compensation award derivative · Stock Option (Right to Buy) 766 — —
Filing: Form 4 (Insider Transaction) Insider: Levy Richard S (Director) Shares: 454
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-18

MDGL insider Form 4 filed for equity award, exercise, or tax withholding

FOUSE JACQUALYN A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 454 — —
A Compensation award derivative · Stock Option (Right to Buy) 766 — —
Filing: Form 4 (Insider Transaction) Insider: FOUSE JACQUALYN A (Director) Shares: 454
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-18

MDGL insider Form 4 filed for equity award, exercise, or tax withholding

Daly James M (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 454 — —
A Compensation award derivative · Stock Option (Right to Buy) 766 — —
Filing: Form 4 (Insider Transaction) Insider: Daly James M (Director) Shares: 454
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-18

MDGL insider Form 4 filed for equity award, exercise, or tax withholding

Brennan Daniel J. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 404 — —
A Compensation award derivative · Stock Option (Right to Buy) 681 — —
Filing: Form 4 (Insider Transaction) Insider: Brennan Daniel J. (Director) Shares: 404
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-06-18

MDGL insider Form 4 filed for equity award, exercise, or tax withholding

BAKER BROS. ADVISORS LP (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 908 — —
A Compensation award 908 — —
A Compensation award derivative · Non-Qualified Stock Options (right to buy) 1,532 — —
A Compensation award derivative · Non-Qualified Stock Options (right to buy) 1,532 — —
Filing: Form 4 (Insider Transaction) Insider: BAKER BROS. ADVISORS LP (Director) Shares: 1,816
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-01

MDGL insider Soergel David (Chief Medical Officer) sold 1,042 shares (~$516.6K)

Soergel David, listed as Chief Medical Officer at MADRIGAL PHARMACEUTICALS, INC., reported an open-market sale of 1,042 MDGL shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 1,042 $495.74 $516.6K
Filing: Form 4 (Insider Transaction) Insider: Soergel David (Chief Medical Officer) Shares: 1,042 Est. Value: $516.6K
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 5 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Madrigal Pharmaceuticals, Inc. has 5 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Large Proposed Insider Sale 2026-09-28

MDGL Form 144 filed for proposed insider sale by PAUL FRIEDMAN (50,000 shares) ~$25.83M

PAUL FRIEDMAN filed a Form 144 with the SEC indicating intent to sell MDGL (MADRIGAL PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: PAUL FRIEDMAN Shares: 50,000 Est. Value: $25.83M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-11

MDGL Form 144 filed for proposed insider sale by WILLIAM SIBOLD (5,221 shares) ~$2.78M

WILLIAM SIBOLD filed a Form 144 with the SEC indicating intent to sell MDGL (MADRIGAL PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: WILLIAM SIBOLD Shares: 5,221 Est. Value: $2.78M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-09-09

MDGL Form 144 filed for proposed insider sale by William John Sibold (6,362 shares) ~$3.40M

William John Sibold filed a Form 144 with the SEC indicating intent to sell MDGL (MADRIGAL PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: William John Sibold Shares: 6,362 Est. Value: $3.40M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-20

MDGL Form 144 filed for proposed insider sale by Shannon Kelley (664 shares) ~$337.0K

Shannon Kelley filed a Form 144 with the SEC indicating intent to sell MDGL (MADRIGAL PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Shannon Kelley Shares: 664 Est. Value: $337.0K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-07-20

MDGL Form 144 filed for proposed insider sale by William Sibold (2,500 shares) ~$1.38M

William Sibold filed a Form 144 with the SEC indicating intent to sell MDGL (MADRIGAL PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: William Sibold Shares: 2,500 Est. Value: $1.38M
View on SEC EDGAR → Open Filing Document →
Material Events 3 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 3 in this period for Madrigal Pharmaceuticals, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-12

MDGL filed 8-K — material company event

MADRIGAL PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-30

MDGL filed 8-K — material company event

MADRIGAL PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-06-17

MDGL filed 8-K — material company event

MADRIGAL PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Madrigal Pharmaceuticals, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-07-30

MDGL filed Quarterly Report (10-Q)

MADRIGAL PHARMACEUTICALS, INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Madrigal Pharmaceuticals, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on MDGL. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — MDGL SEC Filings

More Tools for MDGL

MDGL Full Stock Analysis MDGL Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper MDGL analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the MDGL stock analysis page.

MDGL Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer